European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
Genetic susceptibility, risk prediction, and druggable targets for oropharyngeal cancer: a UK Biobank study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Junhong, Qiu Ke, Rao Yufang, Cheng Danni, Song Yao, Shao Xiuli, Jiang Chuanhuan, Shu Tao, Xu Wei, Zhao Yu, Ren Jianjun
Аннотация
PURPOSE: This study aimed to systematically identify and annotate oropharyngeal cancer (OPC) genetic risk, construct OPC risk prediction models, and identify candidate drug targets for OPC treatment.
METHODS: The OPC genome-wide association study was conducted in the UK Biobank involving 208 OPC patients and 328,248 healthy individuals. Functional annotations were performed using the FUMA website and the Sclinker statistical framework. OPC risk prediction models were constructed using logistic regression. Mendelian randomization (MR) was employed to identify potential OPC-related drug target genes.
RESULTS: We identified 43 OPC risk genetic variants with p < 1E-06, which mapped to 7 independent loci. We also revealed significant tissue-level OPC single nucleotide polymorphism heritability enrichments in heart, kidney, and muscle, and cell-type specific enrichments in B cells, T cells, endothelial cells, epithelial cells, and fibroblasts. We further constructed four OPC risk prediction models, and the fully-adjusted model demonstrated moderate discriminative ability in internal validation. Additionally, MR analysis identified 160 nominate OPC-associated candidate druggable genes using expression/protein quantitative trait loci as instrumental variables. Drugs targeting these genes, such as Daunorubicin, Gefitinib, and Ibrutinib had been approved as anti-cancer agents.
CONCLUSION: These results advanced our understanding of the genetic architecture of OPC and provided insights into its risk prediction and potential drug targets, contributing to future development of improved OPC prevention and treatment strategies.
METHODS: The OPC genome-wide association study was conducted in the UK Biobank involving 208 OPC patients and 328,248 healthy individuals. Functional annotations were performed using the FUMA website and the Sclinker statistical framework. OPC risk prediction models were constructed using logistic regression. Mendelian randomization (MR) was employed to identify potential OPC-related drug target genes.
RESULTS: We identified 43 OPC risk genetic variants with p < 1E-06, which mapped to 7 independent loci. We also revealed significant tissue-level OPC single nucleotide polymorphism heritability enrichments in heart, kidney, and muscle, and cell-type specific enrichments in B cells, T cells, endothelial cells, epithelial cells, and fibroblasts. We further constructed four OPC risk prediction models, and the fully-adjusted model demonstrated moderate discriminative ability in internal validation. Additionally, MR analysis identified 160 nominate OPC-associated candidate druggable genes using expression/protein quantitative trait loci as instrumental variables. Drugs targeting these genes, such as Daunorubicin, Gefitinib, and Ibrutinib had been approved as anti-cancer agents.
CONCLUSION: These results advanced our understanding of the genetic architecture of OPC and provided insights into its risk prediction and potential drug targets, contributing to future development of improved OPC prevention and treatment strategies.